GUIDANCE DOCUMENT ON DIRECTIVE 2005/50/EC ON THE RECLASSIFICATION

Similar documents
Brussels, 12 June 2014 COUNCIL OF THE EUROPEAN UNION 10855/14. Interinstitutional File: 2012/0266 (COD) 2012/0267 (COD)

NOTE TO THE HEADS OF NATIONAL AGENCIES

EUROPEAN PARLIAMENT Committee on the Environment, Public Health and Food Safety

COMMISSION IMPLEMENTING REGULATION (EU)

Special Rules of Accreditation for Certification Bodies of Quality Systems

COMMISSION DIRECTIVE 2011/18/EU

Annex. Provisions on auditing notified conformity assessment bodies in the framework of Article 34 3 of the Agency Regulation 1

Guidance for applicants requesting scientific advice

Guide to Incident Reporting for In-vitro Diagnostic Medical Devices

COMMISSION DELEGATED DIRECTIVE../ /EU. of

State aid SA (2015/N) Germany Evaluation plan- Central Innovation Programme for SMEs (Zentrales Innovationsprogramm Mittelstand ZIM 2015)

GUIDELINES ON MEDICAL DEVICES CLINICAL INVESTIGATIONS: SERIOUS ADVERSE EVENT REPORTING

Petition 2011/102 of Carmel Berry and Charlotte Korte

Official Journal of the European Union. (Non-legislative acts) REGULATIONS

Specific Call for Proposals Mainstreaming Corporate Social Responsibility (CSR) Among SMEs Grant Programme 2005

DRAFT OPINION. EN United in diversity EN. European Parliament 2018/0018(COD) of the Committee on Industry, Research and Energy

REACH Pre-registration Questions and Answers

The Role and Responsibilities of the Medical Physicist in MRI in Europe

IVDD revision changes to the European regulation of in-vitro diagnostic (IVD) Medical Devices. Med-Info. TÜV SÜD Product Service GmbH

Medical devices briefing for patients: Patient safety in the new Regulation

ICTpsp I C T P O L I C Y S U P P O R T P R O G R A M M E. CIP ICT PSP Pilots A, Pilots B, Thematic Networks, Best Practice Networks, PPI Pilots

Secretary-General of the European Commission, signed by Mr Jordi AYET PUIGARNAU, Director

Guide to Incident Reporting for General Medical Devices and Active Implantable Medical Devices

COUNCIL OF THE EUROPEAN UNION. Brussels, 29 May /06 COSDP 376 PESC 460 CIVCOM 207 FIN 207 CSC 26 CAB 19 BUDGET 27

Education, Audiovisual and Culture Executive Agency

Official Journal of the European Union

CHEMICALS (Classification, Labelling, Packaging of substances and mixtures -CLP) Screening Meeting EU Serbia June 2013

EUROPEAN FEDERATION OF NURSES ASSOCIATIONS (EFN) CONSTITUTION

EUROPEAN COMMISSION DIRECTORATE-GENERAL FOR HUMANITARIAN AID - ECHO

25/02/18 THE SOCIAL CARE WALES (REGISTRATION) RULES 2018

Preparatory action. ERASMUS for young entrepreneurs 21/G/ENT/ERA/11/311A

REACH Evaluation. Graham Lloyd Regulatory/Technical. REACH in Practice Conference 1 June, Steptoe & Johnson LLP & Regulatory Compliance Ltd

FRAMEWORK PARTNERSHIP AGREEMENT FOR ACTION GRANTS FRAMEWORK AGREEMENT NUMBER [ ] SUPPORT FOR TRAINING

25/02/18 THE SOCIAL CARE WALES (REGISTRATION) RULES 2018

Procedure for handling applications for authorisation and review reports under REACH

Education, Audiovisual and Culture Executive Agency GRANT DECISION FOR AN ACTION. Decision Nr

Annex 4.3 Notes of session 1

Brussels, 19 December 2016 COST 133/14 REV

GRANT APPLICATION FORM VP/2015/004

JOINT DECLARATION ON THE PROMOTION AND THE ENFORCEMENT OF CANCER PATIENTS RIGHTS

DRAFT AGENDA FOR THE MEETING OF THE STANDING COMMITTEE AND OF THE WORKING GROUP PLANT PROTECTION PRODUCTS - LEGISLATION 13 February 2004

Changes in the Medical Device Legislation; the day after. Jan Bart Hak 1

The Nursing and Midwifery Order 2001 (SI 2002/253)

Health System Outcomes and Measurement Framework

Medical Devices and Device-Led Combination Products; Voluntary Malfunction Summary

Therefore the provision of medicines is an area for which a Community regulatory framework should be properly supervised to ensure full and

GRANT APPLICATION FORM VP/2018/013

Public Service of Wallonia

Preparatory action. ERASMUS for young entrepreneurs ENT/ERA/10/411

Guidance on the Biocidal Products Regulation

Guidance on the preparation of dossiers for harmonised classification and labelling (CLH) under Regulation (EC) No.

Railway Interoperability and Safety Committee. Working document

DECISION. No. xx/xx (20xx) (date)

MILITARY SPECIFICATION SIMULATOR, SURFACE-TO-AIR MISSILE (SMOKEY SAM SIMULATOR) SMU-124/E

Recommendations on outsourcing to cloud service providers (EBA/REC/2017/03)

Payments Enterprise Ireland Payments 8 Company Payments 8 Eligible Costs 9

(Billing Code ) Defense Federal Acquisition Regulation Supplement: Costs. Related to Counterfeit Electronic Parts (DFARS Case 2016-D010)

Free movement of professionals and recognition of professional qualifications in the EU

Australian Standard. Clinical investigations of medical devices for human subjects. Part 1: General requirements AS ISO ISO :2003

U.S. - EC MRA Pharmaceutical Good Manufacturing Practices Annex. SECTORAL ANNEX FOR PHARMACEUTICAL GOOD MANUFACTURING PRACTICES (GMPs) CHAPTER 1

ANNEXES. to the COMMISSION DELEGATED REGULATION (EU).../...

EA Cross Border Accreditation. Policy and Procedure for. Cross Border Cooperation. Between EA Members

GRANT APPLICATION FORM VP/2016/010

GRANT APPLICATION FORM VP/2018/005

Technical specifications for Interoperability (TSIs)

Regulatory and ethics bodies involved in approval process

FlexoStretch. Product Description. Instruction Guide

Important dates. Contact Persons Ir. Annette Bastiaens /

Introduction. Advanced practice in nursing and midwifery has developed internationally and nationally.

COMMISSION IMPLEMENTING DECISION. of

CMDv/BPG/002. BEST PRACTICE GUIDE for Veterinary Decentralised Procedure (DCP)

GRANT APPLICATION FORM VP/2018/007

Recommendation 029 E Best Practice for Investigation and Inquiry into HSE Incidents

Guidance for the Tripartite model Clinical Investigation Agreement for Medical Technology Industry sponsored research in NHS Hospitals managed by

(Non-legislative acts) REGULATIONS

The Environmental Noise (England) Regulations 2006

CONTRACT SPECIFICATION

Public Service of Wallonia

MINIMUM CRITERIA FOR REACH AND CLP INSPECTIONS 1

CLP Regulation Recent implementation and issues. Workshop "Product Stewardship and PROCESS SAFETY 30/11/2017 Dr. Blanca Serrano

Opinion No 13/2016. Technical records

Regulation on the implementation of the European Economic Area (EEA) Financial Mechanism

Hospital Naming Directive

This document is meant purely as a documentation tool and the institutions do not assume any liability for its contents

Topical Peer Review 2017 Ageing Management of Nuclear Power Plants

to the Public Consultation on the Paper of the Services of DG Competition Containing Draft Guidelines on Regional State Aid for

High Level Pharmaceutical Forum

Application form for Commissioning Generation Facility Registration by a Market Participant. including explanatory notes

Contents A. INTRODUCTION... 2 A1. Purpose, scope and other addressees of the report... 2 A2. Significant organisational changes affecting the NSA...

Chapter 6 Section 3. Hospital Reimbursement - TRICARE DRG-Based Payment System (Basis Of Payment)

GUIDANCE NOTE Introduction

European Commission s proposal for a Regulation on Medical Devices (2012/0266 (COD)) EPF Position Statement

510(k) Clinical Data Requirements: Current Status and Considerations for Clinical Studies

REGULATION OF THE EUROPEAN PARLIAMENT AND OF THE COUNCIL

REACH-IT Industry User Manual

Law on Medical Devices

Work of Internal Auditors

Grünenthal Norway AS - Methodological Note

Guidance on the Biocidal Products Regulation

Trust Fund Grant Agreement

Transcription:

Ref. Ares(2015)2027431-13/05/2015 EUROPEAN COMMISSION ENTERPRISE AND INDUSTRY DIRECTORATE-GENERAL Consumer goods Cosmetics and Medical Devices Brussels, 12 January 2007 DG ENTR Unit F3/JB D(2006) GUIDANCE DOCUMENT ON DIRECTIVE 2005/50/EC ON THE RECLASSIFICATION OF HIP, KNEE AND SHOULDER JOINT REPLACEMENTS 1. Introduction The purpose of this document is to provide clarification on a number of points to help ensure a common interpretation of Commission Directive 2005/50/EC on the reclassification of hip, knee and shoulder joint replacements in the framework of Council Directive 93/42/EEC concerning medical devices (the Directive). It was endorsed by the Commission s Medical Device Expert Group, MDEG, at its meeting of the 12 th 13 th December 2006. The Directive requires that the implantable component parts of total hip, knee and shoulder replacement system to be classified, by derogation to the rules contained in Annex IX of Directive 93/42/EEC, as class III medical devices. Member States must apply the provisions of the Directive by the 1 st September 2007 with a transition period lasting until 1 st September 2009, for devices currently approved under Annex II, and until 1 st September 2010, for devices currently approved under Annex VI in conjunction with Annex III. As devices covered by Annex III plus VI are not heavily affected in terms of conformity assessment, this guidance primarily concerns devices currently assessed under Annex II of Directive 93/42/EEC. 2. Points of clarification 2.1 Scope Questions have arisen as to the implants that are reclassified. These questions centre around the phraseology in Articles 1 and 2 and in particular the use of the phrase implantable component part : Article 1 By way of derogation from the rules set out in Annex IX to Directive 93/42/EEC, hip, knee and shoulder replacements shall be reclassified as medical devices falling within class III. Article 2 Commission européenne, B-1049 Bruxelles / Europese Commissie, B-1049 Brussel - Belgium. Telephone: (32-2) 299 11 11. Office: BREY 10/156. Telephone: direct line (32-2) 2932 2 298 50 24. Fax: (32-2) 2932 2 296 64 67. Page 1 of 6

For the purpose of this Directive, a hip, knee or shoulder replacement means an implantable component part of a total joint replacement system which is intended to provide a function similar to that of either a natural hip joint, a natural knee joint or a natural shoulder joint. Ancillary components (screws, wedges, plates and instruments) are excluded from this definition. The above construction is deliberate for the following reasons: Within the preamble to the Directive it is explained that the intention of the legislator, on foot of concerns raised by Member States, is to reclassify hip, knee and shoulder joint replacements, by derogation to the normal rules, into class III. In particular, in recital (5) and (6) it is identified that the critical replacements that are the focus of concern are those intended to provide a function similar to that of a natural hip, knee or shoulder joint, i.e., replacements which are weight bearing and/or are subject to dynamic forces, replace both articulating surfaces and are connected directly or indirectly to the corresponding bones (i.e., for total hip replacements: femoral components, whether monoblock or modular, and acetabular components). 1 During discussions at the time of drafting it was understood that these systems were typically placed on the market either as one complete system containing the component parts, or as separate component parts to a system (whereby the surgeon can choose the most suitable combination of different sized and shaped components). Furthermore, it became evident that within these complete systems, or separately supplied component parts, were ancillary components, such as screws, wedges, plates and instruments etc. It is not the intention of the legislator that such component parts are reclassified into class III, as this would not be proportionate. Therefore, it was necessary to explain in the text that rather than reclassifying complete systems, it is only those implantable component parts that are intended to function similar to the joint in question that are reclassified, and not screws, wedges, plates, instruments, cutting templates etc. Further Observations: 1. Total implantable joint replacement systems usually comprise two sets of components: the total joint implant itself comprised of multiple implanted component parts, including implanted load bearing components and ancillary implanted components (e.g. screws, wedges etc.) and the devices and accessories needed to perform the implant such as plates, cutting templates and instruments, etc. 2. The objective of Directive 2005/50/EC is to reclassify as class III, implanted load bearing components that function in a similar way to the natural joint. 3. Ancillary implanted components and other supplied devices and accessories are not subject to reclassification and continue to be classified as per the current classification rules 2 (see also point (4)). 1 EN 12563 Non-active surgical implants Joint replacement implants Specific requirements for hip joint replacement implants (see definitions). 2 see Annex IX 2.2. of Directive 93/42/EEC 2

4. Reclassified component parts are typically placed on the market: a) as separate component parts which are indicated to be used as part of a specified total joint replacement, or b) as one complete system which contains these component parts. Depending on the presentation of this complete system, it may be classified as a whole in class III or subject to the provisions of Article 12 of Directive 93/42/EEC on systems and procedure packs. In any case, it is only the implantable component parts of the system that are classified as class III, and not the various ancillary components mentioned above. Therefore, for hip, knee and shoulder joint replacements, reclassification into class III apply to the load bearing components that function in a similar way to the natural joint. These reclassified components are typically placed on the market: 1. As separate component parts, which are indicated to be used as part of a specified total joint replacement. 2. As a complete total joint replacement (including all component parts and accessories of the total joint replacement). 3. As a complete total joint replacement system or procedure pack (including accessories and instruments, etc.). 2.2 Transitional arrangements With respect to the placing on the market and putting into service of devices approved prior to 1 September 2007, the Directive, under Article 3, paragraphs 3 and 4, makes a distinction in the adequate transitional arrangements between those hip, knee and shoulder replacements that were subject to an Annex II conformity assessment and those that were subject to an Annex III plus VI. Basically, for devices approved under Annex II prior to 1 st September 2007, they cannot be placed on the market or put into service after 1 st September 2009; whereas for devices approved under Annex III plus VI prior to 1 September 2007, they cannot be placed on the market after 1 st September 2010 but they can continue to be put into service after that date This motivation for this distinction is stated in recital 11, citing the need, in the interests of high level of protection of health, for explicit detailed examination of design prior to introduction in general clinical use. (11) In order to achieve the optimal level of safety and health protection and to reduce the design related problems to the lowest level, the design dossier of hip, knee and shoulder replacements, including the clinical data used by the manufacturer to support the claimed performance and the subsequent postmarketing design and manufacturing changes should be examined in detail by the notified body before these devices are introduced in general clinical use. 3

For devices approved under Annex II prior to 1 st September 2007, no such detailed examination is required and thus after 1 st September 2009 they should no longer be placed on the market nor put into service. However, for devices approved under to Annex III plus VI prior to 1 st September 2007, a detailed examination takes place, so the transition period is longer (until 2010) and after this date they should no longer be placed on the market, but they can be still put into service. Directive 93/42/EEC defines putting into service as: (i) putting into service means the stage at which a device has been made available to the final user as being ready for use on the Community market for the first time for its intended purpose; As the final user in this case is the medical professional, the stage at which the device is put into service is when it is available for general clinical use by the surgeon, either by his purchase, or purchase on the surgeon s behalf by a hospital. Therefore replacements referred to in Article 3 paragraphs 3 and 4 approved prior to 1 st September 2007 can be placed on the market until the 1 st September 2009 and 1 st September 2010 respectively. And within these two categories of devices, those approved under Annex II cannot be put into service (sold to surgeons and hospitals for subsequent implantation) after 1 st September 2009, whereas those approved under Annex III plus VI and put on the market before 1 st September 2010, can continue to be put into service after that date. Hip, knee and shoulder replacements that were subject to an Annex II conformity assessment prior to 1 st September 2007 cannot be placed on the market or put into service after 1 st September 2009 without additional conformity assessment. Hip, knee and shoulder replacements that were subject to an Annex III plus VI conformity assessment prior to 1 st September 2007 cannot be placed on the market after 1 st September 2010 without additional conformity assessment, but can be put into service after that date. For hip, knee and shoulder replacements, putting into service can be considered to take place when they are made available to the medical professional. 2.3 Transitional arrangements for products covered by Article 3(1) Devices approved under Annex II before 1 st September 2007. 2.3.1 Issue of EC design-examination assessment after 1 st September 2009. Hip, knee and shoulder replacements that have followed an Annex II conformity assessment procedure before 1 st September 2009, must undergo a complementary design dossier examination (point 4 of Annex II) to be placed on the market and put into service after 1 st September 2009. 4

This raises the question as to what interpretation can be taken for devices that are still in the assessment process but have not yet received a complementary certificate prior to 1 st September 2009. Here, the interpretation is the same as that for all cases where a manufacturer is aware that his device no longer meets the requirements of the Directives, i.e. a device that does not meet the requirements of the Directive should no longer be placed on the market and put into service until it is brought back in compliance (e.g. suspend shipments, quarantine stocks if necessary, etc. until the EC design-examination certificate is issued) It should be noted that Notified Bodies that have begun a design dossier examination prior to 1 st September 2009 may continue the evaluation. Once the EC designexamination certificate is issued, the placing on the market and putting into service, which were suspended, can be resumed. Where the examination of a design dossier will pass the 1 st September 2009 date, a manufacturer must suspend the placing on the market and putting into service of his devices until an EC design-examination certificate is issued. 2.3.2 Issue of EC design-examination assessment reports prior to 1 st September 2007 The Directive entered into force on 1 September 2005. Member States are required to transpose the Directive into national law by the 1 st March 2007 and apply its provisions from 1 st September 2007. In the interests of expediency it has been asked if notified bodies could begin their work on design dossier review under Annex II prior to any of these dates. The Directive, in Article 3 (1) states that: Hip, knee and shoulder replacements that have been subject to a conformity assessment procedure [ ] shall be subject to a complementary conformity assessment under point 4 of Annex II [ ] before 1 September 2009. Therefore, provided that the notified body meets the requirements for competence under the Directive, there is nothing preventing applications and examination of the design dossier beginning any date before the 1 September 2009. However, the Directive, in Article 4, requires Member States to apply the Directive from 1 September 2007. Therefore an EC-design-examination certificate may only be issued after that date. In such cases, in lieu of a certificate, the notified body may issue the manufacturer with a draft report of the review. The notified body and the manufacturer should agree arrangements so that any design changes, as referred to in Annex II paragraph 4.4 of Directive 93/42/EEC, that occur between the date of the draft assessment report and the date the EC-design-examination certificate is expected to be issued, are transmitted to the notified body during this interim period. The Notified Body shall evaluate these design changes to complete the initial report before issuing the final EC-design-examination certificate. 5

Notified bodies can begin their examination at any time; however, an EC designexamination certificate can only be issued after 1 st September 2007 As the design change notification requirement under Annex II paragraph 4.4 is only in effect once a certificate is issued, notified bodies and manufacturers should agree arrangements regarding notification and examination of design changes prior to the issuing of the certificate. 2.4 Examination procedures completed before 1 st September 2009 for devices approved under Annex II prior to 1 st September 2007 Until the 1 st September 2009 cut-off date is reached, hip, knee and shoulder replacements approved under Annex II prior to 1st September 2007, can be placed on the market and put into service as class IIb devices. However, where between 1 st September 2007 and 1 st September 2009 a manufacturer applies for an EC certificate, the hip, knee and shoulder replacements in question are class III medical devices and shall be subject to the corresponding evaluation procedures, in particular with respect to change management, periodic audits, etc. Between 1 st September 2007 and 1 st September 2009, once a manufacturer of a device approved prior to 1st September 2007 under Annex II, applies for an EC certificate, his device is class III and shall be subject to the corresponding evaluation procedures, even if the 1 st September 2009 cut-off date has not been reached.